|
No.1
|
27.8y (1–65)
|
SR grade II–IV GVHD
|
3 (children: 2–7 adults: 2–11)
|
1.5 (0.8–3.1)
|
OR:67.5 CR:27.5
|
N/A
|
1y:50 2y:38.6 median survival time:1.1y
|
2.8y
|
Introna et al. [54]
|
|
No.2
|
44.9y (1.3–68.9)
|
SR grade II–IV aGVHD
|
3 (1–4)
|
1.8 (0.9–2.5)
|
CR:25
|
N/A
|
1y:44
|
150d
|
Te Boome et al. [71]
|
|
No.7
|
21–66y
|
refractory acute or chronic GVHD
|
aGVHD:1–4 cGVHD:1–3
|
0.2–2.9
|
N/A
|
exact time unknown:aGVHD:OR:70 CR:10 cGVHD:OR:50 CR:12.5
|
N/A
|
N/A
|
Pérez-Simon et al. [55]
|
|
No.12
|
≤ 18y
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
https://clinicaltrials.gov/ct2/show/results/NCT02379442?term=02379442&draw=2&rank=1
|
|
No.14
|
58y (5–69)
|
grade II–IV SR aGVHD
|
1/2
|
1–2 or 3–4
|
OR:40.6 CR:21.9 (30 d)
|
90d:OR:46.9 CR:31.2
|
90d:30.3 1y:18.2
|
1y
|
Servais et al. [96]
|
|
No.23
|
50y (20–61)
|
moderate to severe refactory cGVHD
|
6–9
|
2
|
N/A
|
time points varies from different patients:OR:54.5
|
N/A
|
76m
|
Boberg et al. [75]
|
|
No.27
|
7y (0–17)
|
grade II–IV SR aGVHD(excluding skin-only grade II)
|
8
|
2
|
OR:70.4 CR:29.6
|
56d:OR:59.3 CR:31.5 100d:OR:70.4 CR:44.4
|
100d:74.1 180d:68.5
|
180d
|
Kurtzberg et al. [37]
|
|
No.32
|
group A:51y (24–60) group B:46y (36–60)
|
moderate or severe cGVHD
|
1
|
group A:1 group B:3
|
N/A
|
20w:OR:71.4 CR:35.7 42w:OR:71.4 CR:42.9 56w:OR:71.4 CR:57.1
|
56w:71.4 median survival time:45.3w
|
56w
|
Jurado et al. [102]
|
|
No.35
|
18–70y
|
grade II–IV SR aGVHD
|
2
|
cohort A:1 cohort B:2
|
cohort A:OR:62.5 CR:12.5 cohort B:OR:85.7 CR:57.1 total:OR:77.3 CR:33.3
|
100d:cohort A:OR:87.5 CR:50 cohort B:OR:85.7 CR:57.1 total:OR:86.7 CR:53.3
|
100d:cohort A:87.5 cohort B:85.7 total:86.7
|
100d
|
Bloor et al. [39]
|
|
No.42
|
6 m–70y
|
SR grade II–IV aGVHD
|
8 (+ 4)
|
2
|
OR:remestemcel-L group:58 placebo group:54 p = 0.59
|
N/A
|
180d:remestemcel-L group:34 placebo group:42
|
180d
|
Kebriaei et al. [64]
|
|
No.42
|
N/A
|
SR aGVHD
|
8 (+ 4)
|
2
|
N/A
|
100d:OR:remestemcel-L group:82 placebo:73 p = 0.12
|
N/A
|
N/A
|
Martin et al. [88]
|
|
No.43
|
57.5y (35–73)
|
de novo high risk or SR grade I–IV aGVHD
|
2
|
low dose group:2 high dose group:10
|
OR:70 CR:40
|
N/A
|
100d:90 180d:60
|
N/A
|
Soder et al. [103]
|
|
No.44
|
52y (34–67)
|
grade II–IV aGVHD
|
2
|
low dose group:2 high dose group:8
|
low dose group:OR:87.5 CR:87.5 high dose group:OR:100 CR:66.7 total:OR:94 CR:77
|
N/A
|
90d:71.0
|
90d
|
Kebriaei et al. [87]
|
|
No.45
|
36y (21–52)
|
refractory acute and chronic GVHD
|
1
|
1.0
|
N/A
|
1w:OR:40
|
5w:90.9
|
5w
|
Yi et al. [58]
|
|
No.50
|
9.6y (0.3–18.2)
|
grade II–IV SR aGVHD
|
11 (1–24)
|
2
|
OR:65.1 CR:14.1
|
100d:OR:51.5 CR:32.8
|
100d:66.9
|
100d
|
Kurtzberg et al. [37]
|
|
No.50
|
7.8y (0.2–17.5)
|
grade II–IV SR aGVHD
|
10 (1–20)
|
2
|
OR:61.3
|
100d:OR:77
|
100d:57.3
|
100d
|
Kurtzberg et al. [67]
|
|
No.53
|
group1:54.5y (0.9–65.6) group2:48.9y (1.6–72.4)
|
grade II–IV aGVHD
|
group1:1 (1–5) group2:2 (1–6) p = 0.002
|
group1:2.0 (0.9–2.8) group2:1.2 (0.9–2.9) p < 0.001
|
group1:OR:58.8 CR:29.4 group2:OR:100 CR:52.4 p = 0.013 group1 SR patients:OR:46 group2 SR patients:OR:100
|
N/A
|
1y:group1:47 group2:76 p = 0.016 group1 SR patients:31 group2 SR patients:73 p = 0.02
|
N/A
|
Ringden et al. [56]
|
|
No.53
|
49y (1.6–72)
|
grade II–IV aGVHD
|
2 (1–6)
|
1.2 (0.9–2.9)
|
OR:100 CR:52.4
|
56d:OR:95
|
1y:81 2y:67 4y:57 SR patients:4y:55
|
4y
|
Sadeghi et al. [104]
|
|
No.64
|
52y (4–62)
|
SR grade II–III aGVHD
|
8 (5–12)
|
2
|
OR:93 CR:57
|
24w:OR:93 CR:85.7
|
24w:78.6 96w:57.1
|
96w
|
Muroi et al. [34]
|
|
No.65
|
33y (5–66)
|
SR grade III–IV aGVHD
|
4–12
|
2
|
OR:60 CR:24
|
12w:OR:60 CR:52 24w:OR:60 CR:48 36w:OR:52 CR:44
|
52w:48
|
52w
|
Muroi et al. [35]
|
|
No.66
|
41.5y (17–68)
|
severe SR cGVHD
|
4
|
1
|
N/A
|
8w:PR:100
|
exact time unknown:90
|
N/A
|
Kim et al. [28]
|
|
No.69
|
aGVHD:21–61y cGVHD:31–53y
|
grade II–IV SR aGVHD;SR cGVHD
|
aGVHD:2–19 cGVHD:2–11
|
1.7–2.3
|
N/A
|
exact time unknown:aGVHD:OR:92 CR:58 cGVHD:OR:57 CR:29
|
aGVHD:3y:55 cGVHD:median survival time:8m
|
N/A
|
Herrmann et al [74]
|
